Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

SORAFENIB FOR PEAK IDENTIFICATION CRS (15 MG)

SORAFENIB FOR PEAK IDENTIFICATION CRS (15 MG)

ND

DISCOVER
PIPERACILLIN IMPURITY I CRS (15 MG)

PIPERACILLIN IMPURITY I CRS (15 MG)

ND

DISCOVER
RIOCIGUAT CRS (130 MG)

RIOCIGUAT CRS (130 MG)

ND

DISCOVER
RIOCIGUAT FOR SYSTEM SUITABILITY CRS (15 MG)

RIOCIGUAT FOR SYSTEM SUITABILITY CRS (15 MG)

ND

DISCOVER
RIOCIGUAT FOR FP SYSTEM SUITABILITY CRS (15 MG)

RIOCIGUAT FOR FP SYSTEM SUITABILITY CRS (15 MG)

ND

DISCOVER
PIPERACILLIN IMPURITY N CRS (15 MG)

PIPERACILLIN IMPURITY N CRS (15 MG)

ND

DISCOVER
ACICLOVIR FOR IMPURITY C IDENTIFICATION CRS (0.3 MG)

ACICLOVIR FOR IMPURITY C IDENTIFICATION CRS (0.3 MG)

ND

DISCOVER
LATANOPROST - REFERENCE SPECTRUM (N/A)

LATANOPROST - REFERENCE SPECTRUM (N/A)

ND

DISCOVER
ACICLOVIR FOR IMPURITY G IDENTIFICATION CRS (0.002 MG)

ACICLOVIR FOR IMPURITY G IDENTIFICATION CRS (0.002 MG)

ND

DISCOVER
ACICLOVIR FOR SYSTEM SUITABILITY A CRS (20 MG)

ACICLOVIR FOR SYSTEM SUITABILITY A CRS (20 MG)

ND

DISCOVER
ADRENALINE IMPURITY F CRS (0.008 MG)

ADRENALINE IMPURITY F CRS (0.008 MG)

ND

DISCOVER
TERIFLUNOMIDE CRS (15 MG)

TERIFLUNOMIDE CRS (15 MG)

ND

DISCOVER